Company news

Wave Life Sciences Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

October 27, 2026

Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026

October 20, 2026

Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

October 19, 2026

Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference

October 13, 2026

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

October 1, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

September 30, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

September 23, 2026

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

September 22, 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3, 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

July 23, 2026

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

July 7, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

June 24, 2026

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

May 18, 2026

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026

Amendment to Annual Report (Form 10-K/A)

April 30, 2026

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

April 27, 2026

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

April 22, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

April 21, 2026

Wave Life Sciences Announces Proposed Redomiciliation to the United States

April 14, 2026

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

March 25, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

March 4, 2026

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

February 19, 2026

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

February 2, 2026

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

January 12, 2026

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 8, 2025

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 7, 2025

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

December 7, 2025

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

December 6, 2025

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 9, 2025

Wave Life Sciences to Present at Upcoming Investor Conferences

November 6, 2025

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

November 3, 2025

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

November 3, 2025

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

October 28, 2025

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

October 28, 2025

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

September 17, 2025

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

September 2, 2025

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

July 29, 2025

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

July 22, 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 19, 2025

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 27, 2025

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

April 30, 2025

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

March 25, 2025

Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 97 decks. Every deck is listed under its year.